Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

54.87 +0.57 (+1.05%)
Official Closing Price Updated: 7:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
95 96 Next >
Levi &amp; Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Novo Nordisk Stock Sinks—But Is a Bottom Finally In?
Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings 
Via MarketBeat
EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data
Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss from a single dose. 
Via Benzinga
Dollar's Worst Start Since 1970s Could Dent European Corporate Profits
 
Via Benzinga
Massive News for Novo Nordisk Stock Investors!
Management told investors to expect slower sales and profit growth in 2025. 
Via The Motley Fool
Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On?
Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations. 
Via Benzinga
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A High-Quality Dividend Stock with Strong Growth and Stability
NVO offers dividend investors a strong 3.62% yield, 16.56% growth, and high profitability, backed by solid financial health and growth potential. 
Via Chartmill
NOVO NORDISK A/S (NYSE: NVO) INVESTOR ALERT – Investors With Large Losses in Novo Nordisk A/S Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
IBD 50's Hims & Hers Plummets 9% On Second-Quarter Sales Miss
The company reiterated its sales outlook for the year, despite coming in with lighter-than-expected second-quarter sales. 
Via Investor's Business Daily
Topics ETFs Earnings
Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A/S (NYSE: NVO) After Class Action Filing
From Berger Montague
Via GlobeNewswire
This Biotech Stock Could Soar on Upcoming Clinical Data
This weight loss drugmaker may be significantly undervalued right now. 
Via The Motley Fool
Stock Market Today: US Stocks Likely To Open Higher Despite Weak Jobs Report—Palantir, Vertex Pharma In Focus
US stock futures are up on Monday after ending Friday deep in the red, following a disappointing jobs report by Bureau of Labor Statistics. 
Via Benzinga
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio?
Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts. 
Via Benzinga
Why Is Novo Nordisk Stock Crashing, and Is It a Buying Opportunity?
Competition from all sides is causing Novo Nordisk to revise its expectations for 2025. 
Via The Motley Fool
Benzinga Bulls And Bears: Celestica, Carvana, Novo Nordisk — And Fed Holds Rates Despite Trump Pressure
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Topics Economy Government
Why Eli Lilly Stock Topped the Market Today
Zepbound could benefit handsomely if an apparently planned government program is implemented. 
Via The Motley Fool
Topics Government
Why Novo Nordisk Stock Bumped Higher on Friday
There might be a new way for certain users to defray their costs for obesity treatments. 
Via The Motley Fool
Topics Government
Will Hims & Hers Fall Along With Novo Nordisk?
Novo Nordisk shares are trading as low as 35% of their 52-week highs, making Hims & Hers investors nervous whether a selloff is coming. 
Via MarketBeat
Why Novo Nordisk Stock Imploded This Week
Could this be a buying opportunity amid historically low valuations? 
Via The Motley Fool
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under Medicaid, Medicare
The Washington Post reported on Friday that state Medicaid programs and Medicare Part D insurance plans will be able to voluntarily choose to cover Ozempic, Wegovy, Mounjaro, and Zepbound for patients... 
Via Stocktwits
Topics Government
Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients
FDA approves Novo Nordisk's Alhemo for hemophilia A and B without inhibitors, following strong Phase 3 results showing reduced bleeding episodes. 
Via Benzinga
Trump Administration Plan Signals Shift Toward Weight-Loss Drug Coverage For Medicare Patients
The Trump administration is planning a five-year test allowing states to cover weight-loss drugs like Ozempic and Wegovy under Medicare and Medicaid programs. 
Via Benzinga
Topics Government
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
From Pomerantz LLP
Via GlobeNewswire
Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines
Regeneron Q2 revenue rose 4% to $3.68 billion, driven by Dupixent and antibody profits, while FDA delays impacted Eylea HD and odronextamab approvals. 
Via Benzinga
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. 
Via Benzinga
Topics Government
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
95 96 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.